Эта запись также доступна на: 
Russian 
French 
Portuguese (Brazil)
The rapid development of modern technologies makes investing in them a promising endeavor. The list of profitable areas also includes investments in medicine.
Summary of budgets
Today, investment in medicine and healthcare in general is reaching enormous proportions. Funds go there through public health organizations, research grants to educational institutions and centers engaged in research activities. This year’s NIH budget will grow by 5 percent over last year, reaching $39 billion.
In the People’s Republic of China, investments in this area are increasing by approximately 10% annually. Also, the PRC is set to overtake the United States early in the next decade in the percentage of GDP allocated to the scientific segment devoted to longevity and health support.
In addition, pharmacists are investing heavily in companies specializing in the development and production of instruments and high-tech equipment. Their segment allocates a huge amount of money to create new drugs. In the current year, investments in this sphere will grow in the neighborhood of 3% and will total 177 billion dollars.
Over the past 4 years, firms have been able to raise about $345 billion with debt and equity funds going to support basic research projects and being the source of funding for a wide variety of clinically oriented trials.
Enterprises favorable for investment in medicine
The results of their activities are in demand in various fields of medicine:
- Illumina (has a leading position in gene sequencing).Currently holds approximately three-quarters of its core market. Conducts research on the human genome to find ways to analyze gene mutations caused by disease. Today, nine-tenths of sequenced genetic material comes from it. In the year before last, switched to the new Novaseq 6000, which has higher capacity. It also trades in instruments containing microarrays. These are used to analyze genetic material. There is a possibility of rapid growth of securities of this company, caused by increased sales of their products.
- Thermo Fisher Scientific (specializes in the trade of a large variety of equipment used in laboratories).The products offered by the company have a very wide range, including both equipment for scientific work and consumables. It is of interest, among others, to those who are interested in investing in biotechnology and in research to improve animal health or food quality. Each year, the company’s average realization percentage growth rate reaches approximately 11%. In the year that ended, the bottom line was $24.1 billion. Two years earlier, it bought out FEI, which became a Nobel Prize winner for its innovations in electron microscopy.
- Aligent Technologies and Danaher (a pair of firms that trade in laboratory instrumentation as well as instruments used in diagnostics).Aligent is involved in a number of medical fields, such as molecular diagnostics or the creation of devices involved in the creation of innovative drugs.Danaher, for its part, expects to generate $20 billion in revenue this year. Approximately 30% of this will come from the life sciences sector. In addition, it is engaged in equipment for diagnostics, dentistry, chemical industry. The potential growth of its securities during the current year is able to reach $125 per share. It is expected to see sales growth in the range of 5%.
- Bio-Techne (belongs to the field that produces components for “liquid biopsy”, currently under active development).The company plans to raise its revenue figures by 11% for the current year. In this case, it will reach 753 million dollars. EPS will grow in the neighborhood of 8%, amounting to $4.19 per security.
It is quite fair to believe that the above enterprises will be relevant in modern medicine for many years to come. It is reasonable to expect the value of their securities to rise in the not too distant future.
